Hemorrhagic Fever, Ebola clinical trials

The registry lists 104 studies for Hemorrhagic Fever, Ebola across more than 10 countries. 13 are recruiting or about to start. 102 of them are mainly about Hemorrhagic Fever, Ebola (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-29.

Get an email when these change. Save the Hemorrhagic Fever, Ebola studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 69
Status unknown: 8
Not yet recruiting: 7
Terminated: 7
Withdrawn: 5
Recruiting: 4

Phase

Phase 1: 46
Phase 2: 28
Phase 3: 15
Phase 4: 4

Where

United States: 28
Sierra Leone: 11
Uganda: 10
Liberia: 10
Guinea: 9
United Kingdom: 7

Who runs them

National Institute of Allergy and Infectious Diseases (NIAID) (20) · University of Oxford (8) · Janssen Vaccines & Prevention B.V. (7) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (6) · London School of Hygiene and Tropical Medicine (5) · Institute of Tropical Medicine, Belgium (5) · ANRS, Emerging Infectious Diseases (3) · Jiangsu Province Centers for Disease Control and Prevention (3)

What is being tested here

Drugs under test in Hemorrhagic Fever, Ebola studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Phase 3	All
Favipiravir	0	2
Recombinant zaire ebolavirus KIKWIT-95 envelope glycoprotein modified vesicular stomatitis virus	1	2
Remdesivir	0	2
Ansuvimab	0	2
V920	0	1
Matrix-M	0	1
Rocakinogene sifuplasmid	0	1
Poly ICLC	0	1
Galidesivir	0	1
Azithromycin	0	1

Coming up

3phase 3 studies under way

7studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7, phase 3 first

Apr 2027Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo · Phase 3 · Jean-Pierre Van geertruyden
Aug 2027EBOla Post-Exposure Prophylaxis · Phase 3 · ANRS, Emerging Infectious Diseases
Nov 2026REVIVE (Response to the Ebola Virus Vaccine) · Tulane University
Apr 2027A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health · International AIDS Vaccine Initiative
Jun 2027BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies · Epicentre
Aug 2027Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers · ANRS, Emerging Infectious Diseases
Aug 2027Immunology of Ebola Vaccine · Emory University

Who these studies take

Of the 4 Hemorrhagic Fever, Ebola studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (100%) take healthy volunteers.

Recruiting studies that take each age, of 4
Age	Women	Men
10	0 (0%)	0 (0%)
18	4 (100%)	4 (100%)
30	4 (100%)	4 (100%)
40	4 (100%)	4 (100%)
50	4 (100%)	4 (100%)
65	2 (50%)	2 (50%)
75	2 (50%)	2 (50%)
85	2 (50%)	2 (50%)

Across all 104 studies, recruiting or not: 61% stop at 75 or younger and 55% at 65; 32% take children; 0% are for women only and 1% for men only; 75% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hemorrhagic Fever, Ebola studies take

Of 16 phase 1 interventional studies under Hemorrhagic Fever, Ebola, half reached primary completion within 16 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	16 mo10–23 · 16 studies	—	—
Phase 2	32 mo4–39 · 13 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination StrategiesOct 29, 2026NCT07903350

Studies

Recruiting first, then most recently updated. Showing 50 of 104. Browse all 104 → or search them.